News

August 15th, 2019 – NIH awards DxDiscovery a Phase II SBIR for development of a rapid diagnostic for tinea capitis and onychomycosis
Tinea capitis (scalp ringworm) is a serious fungal infection that affects 3-8% of children in the United States. Children from disadvantaged socioeconomic backgrounds, sub-Saharan African descent, or other groups that have been traditionally disadvantaged within the health care system are most at risk of infection. (more…)
Read More
April 11th, 2019- NIH awards DxDiscovery a Phase I SBIR for development of Immunoassay for early diagnosis of mucormycosis
Mucormycosis is a devastating invasive fungal infection that has a 47% or greater mortality rate. It predominantly affects immunocompromised individuals, including bone marrow or solid organ transplant recipients, patients with hematological malignancies undergoing chemotherapy, and patients with diabetes mellitus. (more…)
Read More
June 21, 2016 – NIH awards DxDiscovery a Phase II SBIR for development of a rapid diagnostic for pertussis (whooping cough)
Pertussis (whooping cough) is rapidly re-emerging as a serious public health threat in the United States. Current diagnostics (PCR and culture) are slow, expensive and require a high level of user expertise. The goal of this project is to resolve a critical public health need for improved pertussis diagnostics by developing a point-of-care immunoassay that can diagnose early-stage pertussis in minutes, at very low cost, and without the need for specialized equipment or user expertise. (more…)
Read More
June 1, 2014 –DxDiscovery begins work on an NIH-funded Phase I SBIR project to develop a rapid diagnostic for pertussis (whooping cough)
Pertussis (whooping cough) is a serious and potentially life-threatening respiratory disease caused by the bacterium Bordetella pertussis. Worldwide, 18.4 million people become ill with pertussis each year, and 254,000 of these patients die. Despite high vaccine coverage in the United States, there were still over 48,000 pertussis cases reported (more…)
Read More
Department of Defense awards DxDiscovery/University of Nevada, Reno $1M Sequential Phase II SBIR
DxDiscovery is continuing efforts to develop medical countermeasures against melioidosis and glanders. These diseases are caused by Burkholderia pseudomallei and Burkholderia mallei, respectively. B. mallei infections are rare, however, B. pseudoamallei infections are a significant cause of morbidity and mortality in southeast Asia.
Read More
Point of Care immunoassay for early diagnosis of pertussis awarded.
National Institutes of Health , National Institute of Allergy and Infectious Disease award number R43AI109891 was awarded to Principal Scientist Amanda Burnham-Marusich and Thomas Kozel for development of a point of care immunoassay for early diagnosis of pertussis on June, 1st 2014.
Read More
Silver and Blue Article
DxDiscovery was featured in the Winter 2014 edition of Silver and Blue Magazine.
Read More
DxD is Sontag Finalist
DxDiscovery announced as one of seven finalists in Sontag competition.
Read More

